Ephraim Heller

From Wikipedia, the free encyclopedia
Jump to: navigation, search

Ephraim Heller is a prolific inventor and entrepreneur, and the current CEO of SynAgile Corporation.[1] SynAgile is developing new therapies for treatment of Parkinson's disease. In 1992, he was the co-founder and first CEO of TheraSense, which went[2] public and was later sold to Abbott Labs for $1.2 billion.[3] He was also co-founder, chairman and CEO of AngioScore and led the product development and FDA approval. AngioScore was acquired in 2014 for $230 million plus milestone payments. Prior to its acquisition, the company sold more than 300,000 AngioSculpt catheters in over 65 countries around the world. He was previously a Venture Partner at 7 Health Ventures. Heller holds an MBA from Yale School of Management and he has an AB in Physics from Harvard.

Patents[edit]

Ephraim Heller holds over 100 US patents, including patents on blood glucose monitors and photocatalytic materials.[4]

References[edit]

  • Profile in Businessweek
  • Abbott Labs: "In April 2004, Abbott announced it had completed the acquisition of TheraSense, a leader in developing blood glucose self-monitoring devices that require very small blood samples to deliver rapid test results".
  • Abbott's Annual Report for Fiscal Year 2003 featured the acquisition of Therasense on its cover.
  • New York Times, January 14, 2004: "A deal by Abbott Laboratories to buy TheraSense for $1.2 billion in cash to bolster its diabetes drugs sent TheraSense up 31 percent , gaining $6.34, to $26.64. Abbott rose 24 cents, to $44.43."